Skip to search form
Skip to main content
>
Semantic Scholar
Semantic Scholar's Logo
Search
Sign In
Create Free Account
You are currently offline. Some features of the site may not work correctly.
Azixa
National Institutes of Health
Create Alert
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Pharmacophore Modeling, Docking and Molecular Dynamics Studies on Caspase-3 Activators Binding at β-Tubulin Site.
S. S. Bhunia
,
S. Singh
,
S. Saxena
,
A. Saxena
Current computer-aided drug design
2015
Corpus ID: 6610401
Induction of apoptosis by the activation of caspase 3 makes it a promising target for designing anticancer drugs hence an…
Expand
2015
2015
Identification of imidazoquinoline derivatives as potent antiglioma agents.
S. Patil
,
S. Pfeffer
,
W. Seibel
,
L. Pfeffer
,
D. Miller
Medicinal chemistry (Shariqah (United Arab…
2015
Corpus ID: 40597756
Glioblastoma Multiforme (GBM) is a highly fatal disease and new chemotherapeutic agents are desperately needed to treat GBM…
Expand
2015
2015
Phase II Study of Verubulin (Azixa, MPC-6827) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma Multiforme Patients: Incomplete Report on Safety, Tolerability and Responses (P3…
J. Zhu
,
S. Kesari
,
L. Recht
2015
Corpus ID: 69021299
OBJECTIVE: To establish safety, tolerability and efficacy of Azixa when combined with standard of care therapy (SOC) (RT/TMZ) in…
Expand
2014
2014
Effects of the Tumor‐Vasculature‐Disrupting Agent Verubulin and Two Heteroaryl Analogues on Cancer Cells, Endothelial Cells, and Blood Vessels
K. Mahal
,
M. Resch
,
R. Ficner
,
R. Schobert
,
B. Biersack
,
T. Müller
ChemMedChem
2014
Corpus ID: 28662449
Two analogues of the discontinued tumor vascular‐disrupting agent verubulin (Azixa®, MPC‐6827, 1) featuring benzo‐1,4‐dioxan‐6‐yl…
Expand
2010
2010
Phase I Clinical Trial of MPC-6827 (Azixa), a Microtubule Destabilizing Agent, in Patients with Advanced Cancer
A. Tsimberidou
,
W. Akerley
,
+9 authors
R. Kurzrock
Molecular Cancer Therapeutics
2010
Corpus ID: 25878540
MPC-6827 (Azixa) is a small-molecule microtubule-destabilizing agent that binds to the same (or nearby) sites on β-tubulin as…
Expand
2010
2010
Discovery of N-methyl-4-(4-methoxyanilino)quinazolines as potent apoptosis inducers. Structure-activity relationship of the quinazoline ring.
N. Sirisoma
,
Azra Pervin
,
+9 authors
S. Cai
Bioorganic & medicinal chemistry letters
2010
Corpus ID: 32307787
As a continuation of our efforts to discover and develop apoptosis inducing N-methyl-4-(4-methoxyanilino)quinazolines as novel…
Expand
2010
2010
Final report: Combination of MPC-6827 with temozolomide for the treatment of patients with metastatic melanoma.
W. Hwu
,
W. Akerley
,
+5 authors
O. Hamid
2010
Corpus ID: 74443880
8531 Background: MPC-6827 (Azixa) is a microtubule destabilizing agent. This study was designed to establish the safety and…
Expand
2010
2010
A clinical study investigating MPC-6827 with carboplatin in the treatment of patients with relapsed glioblastoma multiforme.
K. Grossmann
,
J. H. Ward
,
+7 authors
R. Jensen
2010
Corpus ID: 73898475
2095 Background: MPC-6827 (Azixa; 4-arylaminoquinazoline) is a microtubule destabilizing agent that achieves high brain…
Expand
2010
2010
Molecular Medicine in Practice Phase I Clinical Trial of MPC-6827 ( Azixa ) , a Microtubule Destabilizing Agent , in Patients with Advanced Cancer
A. Tsimberidou
,
W. Akerley
,
+9 authors
R. Kurzrock
2010
Corpus ID: 15643166
MPC-6827 (Azixa) is a small-moleculemicrotubule-destabilizing agent that binds to the same (or nearby) sites on b-tubulin as…
Expand
2009
2009
Abstract #3606: Azixa, a microtubule formation inhibitor in solid tumors: results of a phase 1 clinical trial
A. Tsimberidou
,
W. Akerley
,
+6 authors
R. Kurzrock
2009
Corpus ID: 71020851
AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO Purpose: Azixa\#8482; (MPC-6827) (4-arylaminoquinazolines) is a small molecule…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE